drugset / Trial / NCT05595460
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Timeline
- Start
- 2022-10-10
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACTINIUM DOTATATE | Other / unclassified | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |